Novamind acquires Utah-based Cedar Psychiatry and Cedar Clinical Research for CAD$3.05 million.
Exploring the companies and themes that make up this emerging and exciting new sector
Big Pharma: Friend or Foe of Psychedelic Drugs?
Big Pharma has strong incentives to embrace psychedelics. But will its predatory business model turn drug companies against these drugs?
Palliative Canadians endure punishing waits while Health Minister delays approval of Psilocybin mushrooms; TheraPsil expands effort to Ontario
More pressure on Ottawa to move forward on legalization of psilocybin.
Psychedelics Investing 101: Creating a Basket of Psychedelics Stocks
Intelligent diversification is the key to investing in this emerging industry.
Are Psychedelics The Answer For Addiction?
Globally, over 1 billion people are substance abusers. The U.S. addiction treatment market is already a $35 billion per year industry. Psychedelic drugs may be the (better) answer.
The Lundquist Institute Accepts a $1.75 Million Anonymous Donation to Improve the Quality of Dying
Funding to evaluate the potential of psilocybin to ease end-of-life distress.
Numinus Announces Short Form Prospectus Offering of Units for Gross Proceeds of Up To $4.05 Million
Numinus is pricing its financing at CAD$0.27 per unit, with warrants priced at CAD$0.40.
Red Light Holland Provides Corporate Update
Red Light Holland released a detailed corporate update that includes operational and financial highlights as well as recent appointments.
Mindleap Health Signs Agreement with Brightmind to Launch Comprehensive Meditation Program
Mydecine is tapping into the spiritual dimension of psychedelics with its own meditation app.
Red Light Holland Places First Order for Psychedelic Truffles Microdosing Packs
Red Light Holland places 10,000-unit order of its psychedelic truffles for distribution in the Netherlands.
MagicMed Industries Inc. Announces Brokered Private Placement with Mackie Research Capital Corporation
MagicMed Industries is seeking to raise CAD$1.5 million via the sale of 6,000,000 common shares.
PharmaDrug Inc. Repays Amounts Owing Under Bridge Loan and Advisory Agreement, Completes Previously Announced Debt Restructuring and Provides Financial Update
Pharmadrug has completed a financial restructuring including retiring ~CAD$1.5 million in debt.